FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Pega: Q1 Results Miss, But Strength In Pega Cloud Offsets

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

PEGA reported total revenue of $430M, missing consensus by $37.2M and declining 10% Y/Y, while non-GAAP EPS of $0.46 missed by $0.23 and fell 39% Y/Y. However, Pega Cloud revenue surged 36% Y/Y to $205M, now representing 47.7% of total revenue and validating the cloud transition thesis. Pega Cloud annual contract value (ACV) acceleration remains the standout metric, growing 29% Y/Y to $906.7M and accelerating from 23% growth in Q1, demonstrating continued strong demand for the company's AI workflow automation platform. Total ACV grew 12% Y/Y to $1.62B, with backlog increasing 16% Y/Y to $2.01B providing revenue visibility. We believe the robust cash flow generation of $206.5M in free cash flow and a solid balance sheet with $474M in cash provides financial flexibility for continued AI investment. Despite near-term profitability pressure, we expect the sustained Pega Cloud momentum and strong ACV growth to support the business transformation.

Related Articles

Asia

Corporate Travel Management Expects to Reverse Up to 118 Million Pounds Sterling of Revenue From Prior Results

Corporate Travel Management (ASX:CTD) now expects to reverse up to 118 million pounds sterling of revenue from fiscal year 2025 and prior years' results, up from a previously flagged amount of 77.6 million pounds sterling, according to a Wednesday filing with the Australian bourse.The development comes after the company hired KPMG to perform a forensic accounting review for certain years, with KPMG identifying areas of concern regarding the recognition of the UK group's concluded customer contracts and other revenue.The company said revenue of up to about 10 million pounds sterling may need to be reversed in the fiscal first-half results, depending on the outcome of commercial discussions with certain customers. The review confirmed that certain customers were charged above the contractual entitlement.Corporate Travel Management has made "significant changes" within its UK business, especially across financial controls and operational processes, it said, adding that the review has not identified any issues in other regions.The company aims to release audited fiscal year 2025 and reviewed fiscal first-half 2026 financial statements in the second quarter of the year.

$ASX:CTD
Asia

Northern Star Resources' Gold Sales Fall in March Quarter

Northern Star Resources (ASX:NST) said that the total gold sold for the March quarter was 380,807 ounces at an all-in sustaining cost (AISC) of AU$2,709 per ounce, according to a Wednesday Australian bourse filing.Total gold sold was 385,441 ounces at an AISC of AU$2,246 per ounce in the March 2025 quarter, an earlier filing showed.The company expects gold sales in fiscal 2026 to exceed 1.5 million ounces, with AISC projected between AU$2,600 and AU$2,800 per ounce.The company reported net cash of AU$320 million after paying a AU$347 million cash dividend, with total cash and bullion holdings amounting to AU$1.18 billion as of March 31.Northern Star Resources' shares shed around 2% in recent Wednesday trade.

$ASX:NST
Asia

Eisai, Merck's Phase 3 Kidney Cancer Drug Combo Trial Fails to Meet Survival Endpoints

Japanese pharmaceutical firm Eisai (TYO:4523) and U.S.-based Merck's experimental combination therapies failed to meet the dual primary endpoints of progression-free survival and overall survival in a Phase 3 trial.The trial was evaluating first-line treatment for advanced clear cell renal cell carcinoma, a form of kidney cancer that accounts for approximately 80% of all cases, according to a joint statement on Tuesday.The LITESPARK-012 study tested two regimens: Keytruda plus Lenvima plus Welireg, and MK-1308A (a co-formulation of Keytruda with an investigational antibody) plus Lenvima, against the established combination of Keytruda and Lenvima in 1,688 patients.An interim analysis revealed that neither experimental combination met the study's two primary goals of improving overall survival and progression-free survival compared with the standard treatment.

$TYO:4523